300452 山河药辅
已收盘 06-03 15:00:00
资讯
新帖
简况
山河药辅（300452）披露2025年年度权益分派实施公告，6月3日股价下跌2.34%
证券之星 · 06-03 17:44
山河药辅（300452）披露2025年年度权益分派实施公告，6月3日股价下跌2.34%
山河药辅：利润分配方案将在股东会通过后的两个月内实施
证券之星 · 06-02 20:52
山河药辅：利润分配方案将在股东会通过后的两个月内实施
山河药辅（300452）披露2025年度股东大会决议公告，5月14日股价下跌1.22%
证券之星 · 05-14
山河药辅（300452）披露2025年度股东大会决议公告，5月14日股价下跌1.22%
山河药辅（300452）2026年一季报简析：增收不增利
证券之星 · 04-24
山河药辅（300452）2026年一季报简析：增收不增利
4月23日山河药辅跌6.31%，中证2000ETF国泰基金重仓该股
证券之星 · 04-23
4月23日山河药辅跌6.31%，中证2000ETF国泰基金重仓该股
图解山河药辅年报：第四季度单季净利润同比增长1565.74%
证券之星 · 04-23
图解山河药辅年报：第四季度单季净利润同比增长1565.74%
山河药辅（300452）披露2026年第一季度可转债转股情况，4月3日股价下跌3.45%
证券之星 · 04-03
山河药辅（300452）披露2026年第一季度可转债转股情况，4月3日股价下跌3.45%
山河药辅（300452）披露5%以上股东减持股份计划实施完毕公告，2月24日股价上涨2.24%
证券之星 · 02-24
山河药辅（300452）披露5%以上股东减持股份计划实施完毕公告，2月24日股价上涨2.24%
山河药辅(300452.SZ)通过美国FDA现场检查
智通财经 · 02-04
山河药辅(300452.SZ)通过美国FDA现场检查
山河药辅（300452）披露关于持股5%以上股东减持股份达到1%整数倍的公告，01月16日股价下跌7.77%
证券之星 · 01-16
山河药辅（300452）披露关于持股5%以上股东减持股份达到1%整数倍的公告，01月16日股价下跌7.77%
1月15日山河药辅（300452）龙虎榜数据：游资瑞鹤仙上榜
证券之星 · 01-15
1月15日山河药辅（300452）龙虎榜数据：游资瑞鹤仙上榜
异动快报：山河药辅（300452）1月15日9点51分触及涨停板
证券之星 · 01-15
异动快报：山河药辅（300452）1月15日9点51分触及涨停板
山河药辅(300452.SZ)发预增，预计2025年度归母净利润同比增长38.16%-62.45%
智通财经网 · 01-14
山河药辅(300452.SZ)发预增，预计2025年度归母净利润同比增长38.16%-62.45%
山河药辅（300452）披露2025年第四季度可转债转股情况，1月5日股价上涨0.9%
证券之星 · 01-05
山河药辅（300452）披露2025年第四季度可转债转股情况，1月5日股价上涨0.9%
山河药辅（300452）披露2025年持续督导培训情况，12月24日股价上涨0.97%
证券之星 · 2025-12-24
山河药辅（300452）披露2025年持续督导培训情况，12月24日股价上涨0.97%
山河药辅：四季度微晶纤维素订单充足价格稳定
证券之星 · 2025-12-10
山河药辅：四季度微晶纤维素订单充足价格稳定
再出手！复星医药产业拟减持山河药辅，这一次套现多少？
投资时报 · 2025-02-25
再出手！复星医药产业拟减持山河药辅，这一次套现多少？
复星医药拟减持山河药辅不超3%股份市值腰斩聚焦核心业务加注AI医药
新浪财经 · 2025-02-24
复星医药拟减持山河药辅不超3%股份市值腰斩聚焦核心业务加注AI医药
山河药辅：股东复星医药因经营需要拟减持不超过3%公司股份
观点网 · 2025-02-23
山河药辅：股东复星医药因经营需要拟减持不超过3%公司股份
加载更多
公司概况
公司名称：
安徽山河药用辅料股份有限公司
所属行业：
医药制造业
上市日期：
2015-05-15
主营业务：
安徽山河药用辅料股份有限公司的主营业务是药用辅料的研发、生产和销售。公司的主要产品是纤维素及衍生物类、淀粉及衍生物类、无机盐类。公司多次获得“中国化学行业药用辅料优秀企业品牌”称号。
发行价格：
14.96
{"stockData":{"symbol":"300452","market":"SZ","secType":"STK","nameCN":"山河药辅","latestPrice":12.52,"timestamp":1780470192000,"preClose":12.82,"halted":0,"volume":2610752,"delay":0,"changeRate":-0.0234,"floatShares":199000000,"shares":234000000,"eps":0.7526,"marketStatus":"已收盘","change":-0.3,"latestTime":"06-03 15:00:00","open":12.81,"high":12.87,"low":12.47,"amount":32844700,"amplitude":0.0312,"askPrice":12.53,"askSize":16,"bidPrice":12.52,"bidSize":144,"shortable":0,"etf":0,"ttmEps":0.7526,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.82,"symbolType":"stock","openAndCloseTimeList":[[1780450200000,1780457400000],[1780462800000,1780470000000]],"highLimit":14.1,"lowLimit":11.54,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":234456278,"isCdr":false,"pbRate":2.85,"roa":"--","peRate":16.635663,"roe":"4.56%","epsLYR":0.75,"committee":0.322091,"marketValue":2935000000,"turnoverRate":0.0131,"status":1,"floatMarketCap":2487000000},"requestUrl":"/m/hq/s/300452/","defaultTab":"news","newsList":[{"id":"2640908476","title":"山河药辅（300452）披露2025年年度权益分派实施公告，6月3日股价下跌2.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640908476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640908476?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:44","pubTimestamp":1780479885,"startTime":"0","endTime":"0","summary":"截至2026年6月3日收盘，山河药辅报收于12.52元，较前一交易日下跌2.34%，最新总市值为29.35亿元。近日，安徽山河药用辅料股份有限公司披露《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案已获股东会审议通过，以总股本234,456,278股扣除已回购股份1,825,500股后的232,630,778股为基数，每10股派发现金3.00元（含税），共计派发69,789,233.40元，不送红股，不以资本公积转增股本。公司可转债在权益分派期间暂停转股，总股本保持不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943167","title":"山河药辅：利润分配方案将在股东会通过后的两个月内实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943167","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640943167?lang=zh_cn&edition=full","pubTime":"2026-06-02 20:52","pubTimestamp":1780404770,"startTime":"0","endTime":"0","summary":"毕竟品牌形象和价值跟公司股价是正相关的，请董秘转告管理层，希望山河牛气冲天山河药辅回复：投资者您好，利润分配方案将在股东会通过后的两个月内实施，敬请关注公司近日将发布的权益分派实施公告。上市公司股价容易受公司之外一些因素的影响短期有所波动，但长期一定和公司价值匹配。山河药辅发展战略清晰，管理层精诚团结，始终聚焦主业稳健经营，行业地位领先，经营业绩持续向好，作为价值投资者应该看到这些“价值”所在。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200044803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635713576","title":"山河药辅（300452）披露2025年度股东大会决议公告，5月14日股价下跌1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635713576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635713576?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:59","pubTimestamp":1778752754,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，山河药辅报收于13.78元，较前一交易日下跌1.22%，最新总市值为32.31亿元。该股当日开盘13.95元，最高13.99元，最低13.69元，成交额达7293.35万元，换手率为2.67%。近日，山河药辅发布《2025年度股东大会决议公告》。公告显示，公司于2026年5月13日召开2025年度股东会，会议由董事会召集，董事长吴长虹主持，采用现场与网络投票相结合方式召开。独立董事在会上作2025年度述职报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400034021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300452","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629828841","title":"山河药辅（300452）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2629828841","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629828841?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:38","pubTimestamp":1777041481,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期山河药辅发布2026年一季报。根据财报显示，山河药辅增收不增利。截至本报告期末，公司营业总收入2.61亿元，同比上升5.45%，归母净利润4705.99万元，同比下降0.25%。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司应收账款状况持有山河药辅最多的基金为中证2000ETF国泰，目前规模为0.32亿元，最新净值1.5377，较上一交易日下跌1.57%，近一年上涨46.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400065560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886189","title":"4月23日山河药辅跌6.31%，中证2000ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886189","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629886189?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:33","pubTimestamp":1776933230,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日山河药辅跌6.31%，收盘报13.81元，换手率7.66%，成交量15.21万手，成交额2.11亿元。重仓山河药辅的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为国泰基金的中证2000ETF国泰。中证2000ETF国泰目前规模为0.32亿元，最新净值1.5622，较上一交易日上涨0.79%，近一年上涨51.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300045059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300452","561370"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629021888","title":"图解山河药辅年报：第四季度单季净利润同比增长1565.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629021888","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629021888?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:38","pubTimestamp":1776879514,"startTime":"0","endTime":"0","summary":"证券之星消息，山河药辅2025年年报显示，当年度公司主营收入9.43亿元，同比上升6.82%；归母净利润1.77亿元，同比上升47.84%；扣非净利润1.59亿元，同比上升57.31%；其中2025年第四季度，公司单季度主营收入2.46亿元，同比上升3.39%；单季度归母净利润4398.86万元，同比上升1565.74%；单季度扣非净利润3955.43万元，同比上升1165.14%；负债率37.32%，投资收益1335.04万元，财务费用1314.37万元，毛利率31.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300003232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624766381","title":"山河药辅（300452）披露2026年第一季度可转债转股情况，4月3日股价下跌3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624766381","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624766381?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:22","pubTimestamp":1775226140,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，山河药辅报收于14.85元，较前一交易日下跌3.45%，最新总市值为34.82亿元。该股当日开盘15.38元，最高15.48元，最低14.83元，成交额达1.02亿元，换手率为3.44%。近日，安徽山河药用辅料股份有限公司发布关于2026年第一季度可转债转股情况的公告。2026年第一季度，共有390张“山河转债”完成转股，合计转成2,930股公司股票。截至2026年3月31日，累计已有2,357张可转债完成转股，公司剩余可转债数量为3,197,643张，剩余票面总金额为319,764,300元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300452","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717782","title":"山河药辅（300452）披露5%以上股东减持股份计划实施完毕公告，2月24日股价上涨2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717782","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613717782?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:18","pubTimestamp":1771942701,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，山河药辅报收于15.97元，较前一交易日上涨2.24%，最新总市值为37.44亿元。安徽山河药用辅料股份有限公司于2026年2月24日发布公告，持股5%以上股东上海复星医药产业发展有限公司通过集中竞价交易方式，在2025年11月24日至2026年1月15日期间减持公司股份2,325,700股，占公司总股本的1.00%，减持均价为16.42元/股。本次减持后，复星医药持有公司股份比例由9.30%下降至8.30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400043923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300452","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608435983","title":"山河药辅(300452.SZ)通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2608435983","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608435983?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:38","pubTimestamp":1770194302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山河药辅(300452.SZ)公告，公司收到美国FDA出具的现场检查报告(EIR),确认本次检查已结束，公司顺利通过FDA现场检查","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"山河药辅(300452.SZ)通过美国FDA现场检查","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0177","300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603992331","title":"山河药辅（300452）披露关于持股5%以上股东减持股份达到1%整数倍的公告，01月16日股价下跌7.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603992331","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603992331?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:59","pubTimestamp":1768575550,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，山河药辅报收于15.54元，较前一交易日下跌7.77%，最新总市值为36.43亿元。公司近日发布公告称，安徽山河药用辅料股份有限公司持股5%以上股东上海复星医药产业发展有限公司于2025年11月24日至2026年1月15日期间，通过集中竞价交易方式减持公司股份2,325,700股，占公司总股本的1.00%。本次权益变动后，复星医药持有公司股份比例由9.30%下降至8.30%。本次减持已履行此前披露的减持计划，不存在违反承诺或法律法规的情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300452","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603603825","title":"1月15日山河药辅（300452）龙虎榜数据：游资瑞鹤仙上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603825?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:38","pubTimestamp":1768469882,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年1月15日公布的交易公开信息显示，山河药辅因日涨幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年1月15日收盘，山河药辅报收于16.85元，上涨20.01%，涨停，换手率20.85%，成交量41.42万手，成交额6.7亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出36.06万元。瑞鹤仙等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300452","BK0239","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603562152","title":"异动快报：山河药辅（300452）1月15日9点51分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603562152","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603562152?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:55","pubTimestamp":1768442126,"startTime":"0","endTime":"0","summary":"证券之星1月15日盘中消息，9点51分山河药辅（300452）触及涨停板。其所属行业化学制药目前下跌。领涨股为山河药辅。1月14日的资金流向数据方面，主力资金净流入69.36万元，占总成交额0.54%，游资资金净流出403.39万元，占总成交额3.11%，散户资金净流入334.02万元，占总成交额2.58%。近5日资金流向一览见下表：山河药辅主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500009537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300452","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603269530","title":"山河药辅(300452.SZ)发预增，预计2025年度归母净利润同比增长38.16%-62.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603269530","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603269530?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:25","pubTimestamp":1768379130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山河药辅 发布2025年度业绩预告，预计全年归属于上市公司股东的净利润1.65亿元至1.94亿元，同比增长38.16%-62.45%。报告期，公司主要产品的业务订单一直较为充足，增长势头明显。报告期，预计非经常性损益对公司净利润的影响额约为1,750万元，主要系暂时闲置资金的理财收益，上年非经常性损益金额为1,826.72万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300452"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601400014","title":"山河药辅（300452）披露2025年第四季度可转债转股情况，1月5日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601400014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601400014?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:24","pubTimestamp":1767608641,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，山河药辅报收于13.5元，较前一交易日上涨0.9%，最新总市值为31.65亿元。该股当日开盘13.37元，最高13.53元，最低13.35元，成交额达7702.91万元，换手率为2.88%。近日，安徽山河药用辅料股份有限公司发布关于2025年第四季度可转债转股情况的公告。公告显示，2025年第四季度期间，共有180张“山河转债”完成转股，合计转为1,352股股票。截至2025年12月31日，累计已有1,967张转债转股，公司剩余可转债为3,198,033张，票面总金额319,803,300元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300452","BK0239","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593700464","title":"山河药辅（300452）披露2025年持续督导培训情况，12月24日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593700464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593700464?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:39","pubTimestamp":1766587198,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，山河药辅报收于13.51元，较前一交易日上涨0.97%，最新总市值为31.67亿元。近日，国元证券股份有限公司发布了关于安徽山河药用辅料股份有限公司2025年持续督导培训情况的报告。公告显示，国元证券作为山河药辅向不特定对象发行可转换公司债券并在创业板上市的持续督导保荐机构，于2025年12月19日对公司董事、监事、高级管理人员、中层以上管理人员及控股股东、实际控制人等相关人员进行了培训。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300452","BK0239","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590375016","title":"山河药辅：四季度微晶纤维素订单充足价格稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2590375016","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590375016?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:12","pubTimestamp":1765329144,"startTime":"0","endTime":"0","summary":"证券之星消息，山河药辅(300452)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司主要产品微晶纤维素四季度价格怎样？还会不会像去年四季度那样出现业绩亏损？山河药辅回复：投资者你好，四季度公司微晶纤维素等主要产品订单充足，价格保持稳定，生产经营状况良好。去年四季度亏损是因为计提商誉减值损失造成的，今年不会再出现这种情况。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300452","BK0177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514554630","title":"再出手！复星医药产业拟减持山河药辅，这一次套现多少？","url":"https://stock-news.laohu8.com/highlight/detail?id=2514554630","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514554630?lang=zh_cn&edition=full","pubTime":"2025-02-25 15:19","pubTimestamp":1740467943,"startTime":"0","endTime":"0","summary":"截至信息发布之时，复星医药产业持有山河药辅的股份总数约为2392.81万股，占山河药辅总股本的10.20%，为持股超过5%的重要股东。近年来，复星医药产业对山河药辅进行了多次减持操作。2024年6月底，基于自身经营需要，复星医药产业对外公布了减持山河药辅股份的计划。据此计算，复星医药产业通过此次减持共计套现约2770.27万元，其持有的山河药辅比例也相应从11.20%调整至10.20%。复星医药产业的减持动作对公司股价或存在影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502251527279891d8fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502251527279891d8fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","600196","BK0096","BK0028","BK0187","02196","BK0183","BK0196","BK0239","BK0175","300452","BK0177","BK0060","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513478517","title":"复星医药拟减持山河药辅不超3%股份市值腰斩聚焦核心业务加注AI医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2513478517","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513478517?lang=zh_cn&edition=full","pubTime":"2025-02-24 19:23","pubTimestamp":1740396210,"startTime":"0","endTime":"0","summary":"2024年7月31日至2024年10月8日，复星医药完成减持232.6万股，减持均价为11.91元/股。以此计算，复星医药套现约2770.27万元。目前，复星医药仍持有山河药辅2392.81万股，占该公司总股本比例为10.2%，为山河药辅第二大股东。业绩方面，2022年、2023年，复星医药连续两年净利润下滑，2024年前三季度净利润再度下滑11.93%至20.11亿元。不过，近年来，复星医药不断处理非核心非战略资产，集中资源聚焦核心业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224193248a251df5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224193248a251df5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","BK0239","BK0177","BK0183","300452","BK0196","600196","BK0012","BK0096","BK0028","BK0187","BK0188","BK0175","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513759975","title":"山河药辅：股东复星医药因经营需要拟减持不超过3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2513759975","media":"观点网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513759975?lang=zh_cn&edition=full","pubTime":"2025-02-23 23:11","pubTimestamp":1740323511,"startTime":"0","endTime":"0","summary":"观点网讯：山河药辅2月23日公告，股东上海复星医药产业发展有限公司因经营需要，计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股，即不超过公司总股本的3%。 山河药辅表示，公司生产经营情况正常。本次拟减持股份的股东不属于公司的控股股东或实际控制人，本次股份减持不会导致公司控制权发生变更，不会对公司治理结构、股权结构及持续性经营产生影响。免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/23231148332588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK0028","BK0012","BK0187","BK0183","BK1593","300452","BK0188","BK0196","BK0239","BK0096","02196","BK1191","BK0177","BK0175","600196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780509819711,"stockEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":-0.1127},{"period":"3month","weight":-0.1597},{"period":"6month","weight":-0.1183},{"period":"1year","weight":-0.0186},{"period":"ytd","weight":-0.0643}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.006},{"period":"6month","weight":0.0464},{"period":"1year","weight":0.2148},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"安徽山河药用辅料股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18353人(较上一季度增加8.00%)","perCapita":"10822股","listingDate":"2015-05-15","address":"安徽省淮南市大通区经济技术开发区河滨路2号","registeredCapital":"23445万元","survey":" 安徽山河药用辅料股份有限公司的主营业务是药用辅料的研发、生产和销售。公司的主要产品是纤维素及衍生物类、淀粉及衍生物类、无机盐类。公司多次获得“中国化学行业药用辅料优秀企业品牌”称号。","listedPrice":14.96},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山河药辅(300452)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山河药辅(300452)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山河药辅,300452,山河药辅股票,山河药辅股票老虎,山河药辅股票老虎国际,山河药辅行情,山河药辅股票行情,山河药辅股价,山河药辅股市,山河药辅股票价格,山河药辅股票交易,山河药辅股票购买,山河药辅股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山河药辅(300452)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山河药辅(300452)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}